ESTRO 2024 - Abstract Book

S2568

Clinical - Urology

ESTRO 2024

2802

Digital Poster

Ultra-hypofractionated radiotherapy in High risk localised prostate cancer

Claudia Colom Pla 1 , Victoria Navarro Aznar 2 , Cristina García Aguilera 1 , María Cerrolaza Pascual 1 , Alberto Lanuza Carnicer 1 , Ana Galán García 1 , Agustina Méndez Villamón 1 1 Miguel Servet Universitary Hospital, Radiation Oncology, Zaragoza, Spain. 2 Clinic Lozano Blesa Universitary Hospital, Radiation Oncology, Zaragoza, Spain

Purpose/Objective:

Our aim is to analyse the progression-free survival (PFS), cancer-specific survival (CSS), overall survival (OS), and toxicities of treatment with 42Gy extracranial stereotactic radiotherapy (SBRT) in patients diagnosed with localised high risk prostate cancer.

Material/Methods:

Patients treated with SBRT of 42Gy, 7Gy per fraction every other day, over the prostate and seminal vesicles volume with a margin of 4mm were prospectively followed up since april 2020 to the present day. The planning CT was performed after rectal preparation and dietary recommendations, with diuresis control, immobilisation with a wedge under the knees and abdominal compressor.

Intensity modulated radiotherapy was applied using a Linear Electron Accelerator with a photon beam energy of 6MV using image guided radiotherapy with Cone-Beam CT every single day.

Follow-up was performed weekly during treatment, at one month, three months and every six months after treatment. Observed toxicities were analysed using the CTCAE v.5.0 scale.

Results:

135 patients with a mean age of 75,74 years were treated. A total of 97,78% received hormonal treatment for 2-3 years.

At a median follow-up of 20,71 months both PFS and OS is 99,26% with a CSS of 100%. Only one patient had a regional nodal relapse 12 months later, which could be treated with radiotherapy and androgen deprivation.

Acute urinary toxicity G1 (polyuria, nycturia and dysuria) was observed in 28,89% and G2 in 8,89%. One patient had acute urinary retention that required placement of a urinary catheter during treatment. G1 acute gastrointestinal toxicity occurred in 8,15% and 1,48% G2. Beyond 6 months, G1 urinary toxicities were reported in 1,48% and 0,74%